The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration

Massimiliano Berretta, Raffaele Di Francia, Chiara De Diviitis, Guglielmo Nasti, Vincenzo Canzonieri, Michele Caraglia, Gaetano Facchini, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.

Original languageEnglish
JournalCurrent Cancer Drug Targets
DOIs
Publication statusPublished - 2018

Fingerprint

Colorectal Neoplasms
Costs and Cost Analysis
Neoplasms
Therapeutics
Critical Pathways
Cholangiocarcinoma
Liver Neoplasms
Pancreatic Neoplasms
Protein-Tyrosine Kinases
Stomach Neoplasms
Molecular Biology
Cause of Death
Anti-Idiotypic Antibodies
Hepatocellular Carcinoma
Adenocarcinoma
Phosphotransferases
Monoclonal Antibodies
Clinical Trials
Drug Therapy
Incidence

Cite this

The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers : Clinical Impact and Cost Consideration. / Berretta, Massimiliano; Di Francia, Raffaele; De Diviitis, Chiara; Nasti, Guglielmo; Canzonieri, Vincenzo; Caraglia, Michele; Facchini, Gaetano; Tirelli, Umberto.

In: Current Cancer Drug Targets, 2018.

Research output: Contribution to journalArticle

@article{a1523a989f5b46ff92525f63ecbc250d,
title = "The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration",
abstract = "Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.",
author = "Massimiliano Berretta and {Di Francia}, Raffaele and {De Diviitis}, Chiara and Guglielmo Nasti and Vincenzo Canzonieri and Michele Caraglia and Gaetano Facchini and Umberto Tirelli",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
doi = "10.2174/1568009617666170208162058",
language = "English",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers

T2 - Clinical Impact and Cost Consideration

AU - Berretta, Massimiliano

AU - Di Francia, Raffaele

AU - De Diviitis, Chiara

AU - Nasti, Guglielmo

AU - Canzonieri, Vincenzo

AU - Caraglia, Michele

AU - Facchini, Gaetano

AU - Tirelli, Umberto

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018

Y1 - 2018

N2 - Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.

AB - Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.

U2 - 10.2174/1568009617666170208162058

DO - 10.2174/1568009617666170208162058

M3 - Article

C2 - 28183250

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

ER -